Engage Bio Acquired by Lilly to Accelerate Development of Non-Viral Genetic Medicines

Eli Lilly is buying gene therapy biotech Engage Bio for up to $202 million

The deal is Lilly's seventh acquisition of 2026 and centers on Engage's non-viral DNA delivery platform, Tethosome

Engage Bio Acquired by Lilly to Accelerate Development of Non-Viral Genetic Medicines

SAN CARLOS, Calif.--(BUSINESS WIRE)--May 20, 2026-

Lilly snaps up Engage to advance non-viral genetic medicines

The acquisition is Lilly’s latest push into genetic medicine, giving it a technology designed to overcome some of the field’s longstanding limitations.

Eli Lilly maintains M&A streak with $202m Engage Bio buyout - Pharmaceutical Technology

Eli Lilly’s takeover of Engage Bio marks the seventh acquisition for the big pharma since the start of 2026.

Engage Bio Acquired by Eli Lilly for up to $202 Million // Cooley // Global Law Firm